Ravi Shah

He has also assisted clients with cross-border commercial agreements, franchising arrangements, procurement tenders, LLP/ partnership agreements and shareholders’ agreements.

He has over 19 years of experience. He joined the Firm in April 2016, after spending over a decade working in the UK where he gained rich and diverse experience in private practice as well as in-house. He has acted for several foreign and domestic clients in various transactions and has handled all aspects, including due diligence, regulatory filings, institute governance and other compliance issues.

His significant experience spreads across sectors and industries, with a particular focus on the pharmaceutical & healthcare, manufacturing, education and FMCG sector.

• Sorbead India and Swambe Chemicals in the acquisition of their respective businesses by Zeochem AG, an affiliate of CPH Group, Switzerland.
• Zenex Animal Health in relation to legal due diligence, drafting and negotiation of the transaction documents associated with the acquisition of 100% stake in Ayurvet (part of the Dabur family).
• Swiss Parenterals in relation to vendor legal due diligence, negotiation of transaction documents along with ancillary documents for its sale of 51% percent equity stake to Eris Lifesciences Limited.
• Leading healthcare group on acquisition of majority stake in a health-tech company.
• One of India’s leading pharmaceutical company in relation to its acquisition of additional minority equity stake in an API manufacturing company from an outgoing non-resident shareholder.
• Global management consulting firm in relation to structuring of its investment in one of India’s largest wellness company.
• Gujarat’s leading pharmaceutical company in relation to legal and regulatory due diligence, corporate restructuring, and potential sale of majority stake held by its founders to a foreign PE investor, as part of a bidding process.
• Puniska Healthcare in acquisition of a manufacturing facility involving legal and regulatory due diligence as well as assistance with the transaction documents.
• A leading private equity investor in its exit from a pharmaceutical manufacturing company headquartered in Gujarat.
• Zydus Group, one of India’s topmost pharmaceutical company, in the divestment of its animal healthcare business to a consortium led by Multiples Alternate Asset Management.
• A global leader in eye health products in restructuring of its Indian subsidiary.
• Procter & Gamble on its acquisition of an OTC drug manufacturing facility from Teva Pharmaceutical as part of a global transaction.
• Kedaara Capital an Indian private equity firm in its investment in a bulk-drug manufacturing company, AMI Lifesciences.
• Tarsons Products a leading laboratory plasticware manufacturer on the sale of its equity to ADV Partners (an Asian PE firm).
• Zydus Cadila Group with its purchase of pharmaceutical products and associated intellectual property rights and licences from the European and Indian subsidiaries of Merck & Co, Inc., USA.
• A leading animal healthcare company with a transaction involving acquisition of another animal healthcare company having operations across India.
• Assisting Indian and non-Indian investors in their overseas direct investment in a Singapore based start-up in the pharmaceutical sector.
• Zydus Hospital on its acquisition of a hospital in Gujarat from Columbia Asia.

• Bar Council of Maharashtra and Goa, India
• Law Society of England & Wales, UK